Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
Status:
Unknown status
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the long-term safety and the antiviral activity of
the optimal doses of LB80380 for additional 48 weeks in treatment-naive patients with chronic
hepatitis B infection compared to entecavir 0.5 mg.